1e
19
1
49
2
2
18
1b
1d
18
44
7e
1d
2 29
1d
25
Benjamin Jacob Samelson-Jones, MD, PhD
88
7e
Assistant Professor of Pediatrics (Hematology) at the Children's Hospital of Philadelphia
28
87
3
61
Attending Physician, Division of Hematology, Children's Hospital of Philadelphia
b4
Member, The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, University of Pennsylvania School of Medicine
98
Co-Director, Cell and Gene Therapy Clinical Training Program, Children's Hospital of Philadelphia
8d
Associate Director, Clinical In Vivo Gene Therapy, Children's Hospital of Philadelphia
11
Department: Pediatrics
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
51
4
3
3
1d
51
Children's Hospital of Philadelphia
37 Colket Translational Research Building, Rm 5028
39 3501 Civic Center Blvd
Philadelphia, PA 19104
26
37 Colket Translational Research Building, Rm 5028
39 3501 Civic Center Blvd
Philadelphia, PA 19104
2e
Office: 267-425-0147
30
f
30
18
Publications
23 a
3
2
29
23 a
Links
bc Search PubMed for articles
6e Blue Sky Profile
73 Ask the Expert, Bloodstream Media
5d Twitter profile
c
4
b
1f
bc Search PubMed for articles
6e Blue Sky Profile
73 Ask the Expert, Bloodstream Media
5d Twitter profile
c
13
Education:
21 8 AB 15 (Physics ) c
28 Amherst College, 2001.
21 7 MS 20 (Biological Sciences) c
3c Albert Einstein College of Medicine, 2006.
21 7 MD c
3c Albert Einstein College of Medicine, 2009.
21 8 PhD 17 (Biophysics) c
3c Albert Einstein College of Medicine, 2009.
c
3
3
3
3
8d
Permanent link21 8 AB 15 (Physics ) c
28 Amherst College, 2001.
21 7 MS 20 (Biological Sciences) c
3c Albert Einstein College of Medicine, 2006.
21 7 MD c
3c Albert Einstein College of Medicine, 2009.
21 8 PhD 17 (Biophysics) c
3c Albert Einstein College of Medicine, 2009.
c
2 29
21
1e
1d
24
2b
29
27
23
129 Lee K, DeSandre A, Samelson-Jones BJ.: An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B. J Thromb Haemost 23(8): 2688-2690, Aug 2025.
149 Doshi BS, Markmann CA, Novak N, Rojas SJ, Davidson R, Chau JQ, Wang W, Carrig S, Rus CM, Samelson-Jones BJ, Small JC, Bhoj VG, George LA.: Use of CD19-targeted Immune Modulation to Eradicate AAV Neutralizing Antibodies. Mol Ther 33(7): 3073-3085, Jul 2025.
136 Azhwar R, Richter CE, Griffin MS, Emly SM, Yaman M, Arruda VR, Samelson-Jones BJ, Shavit JA.: Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis. Blood Adv 9(13): 3136-3148, Jul 2025.
10c Hussain S, Linder G, Press CA, Vossough A, Samelson-Jones BJ.: Hypertension and encephalopathy in a pediatric patient following red blood cell transfusion. Transfusion 65(6): 1196-1202, Jun 2025.
122 Kaczmarek R, Samelson-Jones BJ.: The timely reporting of clinical trial results answers 1 unknown for hemophilia gene therapy: no benefit of prophylactic immunosuppression. J Thromb Haemost 23(5): 1477-1479, May 2025.
182 Rasko JEJ*, Samelson-Jones BJ*, George LA, Giermasz A, Ducore JM, Teitel JM, McGuinn CE, High KA, de Jong YP, Chhabra A, O'Brien A, Smith LM, Winburn I, Rupon J.: Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study. N Engl J Med 392(5): 1508-1517, Apr 2025 Notes: *contributed equally to work.
10e Samelson-Jones BJ.: Ex vivo lentiviral gene therapy for severe hemophilia A: an alternative to recombinant adeno-associated viral-based strategies? Res Pract Thromb Haemost 9(1): 102716, Mar 2025.
f3 Siner JI, Barber-Meyer S, Samelson-Jones BJ, Mech LD, Arruda VR, Crudele JM.: Ancient origin of the furin sequence in the wolf F8 gene. Open Vet J 15(5): 3216-3222, 2025.
e3 Samelson-Jones BJ, George LA, Doshi BS.: Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies. Blood 144(21): 2185-2197, Nov 2024.
2c
7
1d
1f
Selected Publications
1b9 Keselman DJ, Small JC, Seneviratne T, McCague S, Kaschak TL, Yum SW, O'Brien A, Brandsema JF, Diamond T, Loomes KM, Lin KY, Wittlieb-Weber CA, Mayer OH, Daniel SG, Waldman AT, Samelson-Jones BJ, Matesanz SE, George LA.: Real-World Outcomes of Delandistrogene Moxeparvovec Gene Therapy: Motor Outcomes and Emerging Safety Concerns. Mol Ther 15(5): S1525-0016, Oct 2025.129 Lee K, DeSandre A, Samelson-Jones BJ.: An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B. J Thromb Haemost 23(8): 2688-2690, Aug 2025.
149 Doshi BS, Markmann CA, Novak N, Rojas SJ, Davidson R, Chau JQ, Wang W, Carrig S, Rus CM, Samelson-Jones BJ, Small JC, Bhoj VG, George LA.: Use of CD19-targeted Immune Modulation to Eradicate AAV Neutralizing Antibodies. Mol Ther 33(7): 3073-3085, Jul 2025.
136 Azhwar R, Richter CE, Griffin MS, Emly SM, Yaman M, Arruda VR, Samelson-Jones BJ, Shavit JA.: Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis. Blood Adv 9(13): 3136-3148, Jul 2025.
10c Hussain S, Linder G, Press CA, Vossough A, Samelson-Jones BJ.: Hypertension and encephalopathy in a pediatric patient following red blood cell transfusion. Transfusion 65(6): 1196-1202, Jun 2025.
122 Kaczmarek R, Samelson-Jones BJ.: The timely reporting of clinical trial results answers 1 unknown for hemophilia gene therapy: no benefit of prophylactic immunosuppression. J Thromb Haemost 23(5): 1477-1479, May 2025.
182 Rasko JEJ*, Samelson-Jones BJ*, George LA, Giermasz A, Ducore JM, Teitel JM, McGuinn CE, High KA, de Jong YP, Chhabra A, O'Brien A, Smith LM, Winburn I, Rupon J.: Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study. N Engl J Med 392(5): 1508-1517, Apr 2025 Notes: *contributed equally to work.
10e Samelson-Jones BJ.: Ex vivo lentiviral gene therapy for severe hemophilia A: an alternative to recombinant adeno-associated viral-based strategies? Res Pract Thromb Haemost 9(1): 102716, Mar 2025.
f3 Siner JI, Barber-Meyer S, Samelson-Jones BJ, Mech LD, Arruda VR, Crudele JM.: Ancient origin of the furin sequence in the wolf F8 gene. Open Vet J 15(5): 3216-3222, 2025.
e3 Samelson-Jones BJ, George LA, Doshi BS.: Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies. Blood 144(21): 2185-2197, Nov 2024.
2c